Evaluation of residual tumors and recurrence rates of malignant melanoma and non-melanoma skin cancer of head and neck region

Abstract

Objective: In this study, we aimed to evaluate residual tumors and recurrence rates of malignant melanoma (MM) and a non-melanoma skin cancer of (NMSC) head and neck region.

Patients and Methods: Medical data of a total of 398 lesions of 323 patients who underwent surgical excision for a basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma (MM) were retrospectively analyzed. All patients were classified according to age, sex, location of the tumor, histopathological diagnosis, lesion diameter, excision diameter, surgical margin status, and residual lesions and recurrence rates.

Results: There were 244 lesions (61.3%) in 189 males and 154 lesions (38.7%) in 134 females. The most common type of skin cancer was BCC in 268 lesions (67%), followed by SCC in 122 (31%), and MM in eight (2%), respectively. Recurrence was seen in 3% of the NMSC cases and in 25% of the MM cases. There was a statistically significant correlation between the histopathological diagnosis and recurrence rates. Compared to NMSC, MM cases had a higher risk for recurrence (p=0.029).

Conclusion: Our study results suggest that recurrence is associated with the localization and type of the tumor, but not with the age or sex of the patient.

Keywords

• Basal cell carcinoma,Squamous cell carcinoma,Malignant melanoma,Recurrence,Residual tumor

References

1. [1] Scarabello A, Muti P. Epidemiology and prevention of cutaneous tumors. In: Baldi A, Pasquali P, Spugnini E P, eds. Skin Cancer: A Practical Approach. New York: Humana Press, 2014: 17-28. 10.1007/978-1-4614-7357-2_2
2. [2] Guy Jr GP, Thomas CC, Thompson T, Watson M, Massetti G.M, Richardson LC; Centers for Disease Control and Prevention (CDC). Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR - Morb Mortal Wkly Rep 2015: 64:591-6.
3. [3] Gillard M, Wang T S, Johnson TM. Nonmelanoma cutaneous malignancies. In: Chang AE, Ganz PA, Hayes DF, et al., eds. Oncology: An Evidence-Based Approach. New York: Springer, 2006: 1102-18.
4. [4] Jacobs GH, Rippey JJ, Altini M. Prediction of aggressive behavior in basal cell carcinoma. Cancer 1982;49:53-7. doi: 10.1155/2011/496910.
5. [5] Thieu K, Ruiz M, Owens DM. Cells of origin and tumor-initiating cells for nonmelanoma skin cancers. Cancer Lett 2013;338:82-8. doi: 10.1016/j.canlet.2012.05.008.
6. [6] Shashanka R, Smitha BR. Head and Neck Melanoma. ISRN Surgery 2012, Article ID 948302. doi: 10.5402/2012/948302.
7. [7] Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. Am Acad Dermatol 1992; 26:1-26.
8. [8] Ouyang Y H. Skin cancer of the head and neck. seminars in Plastic Surgery. Semin Plas Surg 2010;24:117-26. doi: 10.1055/s-0030-1255329.

9. [9] Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810:120-40.
10. [10] Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 1992; 26:467-84.
11. [11] Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001;344: 97-983
12. [12] Padgett JK, Hendrix J D, Jr. Cutaneous malignancies and their management. Otolaryngol Clin North Am 2001;34:523-53.
13. [13] Fears TR, Scotto J. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest 1983;1:119-26.
14. [14] Scotto J, Fears TR, Fraumeni JF. Incidence of nonmelanoma skin cancer in the United States. NIH Pub No: 83-2433. Bethesda, MD: U.S. Department of Health and Human Services. 1983.
15. [15] Hasan Z, Riffat F. Epidemiology and aetiology of non-melanoma skin cancer. In: Riffat F, Palme CE, Venesss M, editors. Non-Melanoma Skin Cancer of the Head and Neck. New Delhi: Springer, 2015: 1-9. doi: 10.1007/978-81-322-2497-6
16. [16] Lai V, Cranwell W, Sinclair R. Epidemiology of skin cancer in the mature patient. Clin Dermatol 2018;36:167-76. doi:10.1016/j.clindermatol.2017.10.008.
17. [17] Marks R. An overview of skin cancers. Incidence and causation. Cancer 1995;75:607-12.
18. [18] Demirseren DD, Ceran C, Aksam B, Demirseren ME, Metin A. Basal cell carcinoma of the head and neck region: A retrospective analysis of completely excised 331 cases. J Skin Cancer 2014;2014:858636. doi: 10.1155/2014/858636.
19. [19] Tiftikcioğlu YO, Karaaslan O, Aksoy HM, Aksoy B, Koc U. Basal cell carcinoma in Turkey. The Journal of Dermatology 2006; 33: 91-95.
20. [20] Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998:32,: 393-8.
21. [21] Gloster HM. Jr. Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006;55:741-doi: 10.1016/j.jaad.2005.08.063
22. [22] Betti R, Inselvini E, Carducci M, Crosti C. Age and site prevalence of histologic subtypes of basal cell carcinomas. Int J Dermatol 1995;34;174-6.
23. [23] Boi S, Cristofolini M, Micciolo R, Polla E, Palma PD. Epidemiology of skin tumors: data from the cutaneous cancer registry in Trentino, Italy. J Cutan Med Surg 2003;7:300-5. doi: 10.1007/s10227-002-0135-0
24. [24] Revenga AF, Paricio R J F, Vazquez S M M, del Villar S V. Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (north-eastern Spain) 1998-2000: a hospital-based survey. J Eur Acad Dermatol Venereol 2004;18:137-41.
25. [25] Seretis K, Thomaidis V, Karpouzis A, Tamiolakis D, Tsamis I. Epidemiology of surgical treatment of nonmelanoma skin cancer of the head and neck in Greece. Dermatol Surg 2010;36;15-22. doi: 10.1111/j.1524-4725.2009.01379.x.
26. [26] Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002 ;147:41-7.
27. [27] Soyer HP, Rigel DS, Wurm EMT. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma in Dermatology. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Beijing, China: Elsevier Saunders, 2012:1773-93.
28. [28] Czarnecki D, Collins N, Meehan C, O’Brien T, Leahy S, Nash C. Basal-cell carcinoma in temperate and tropical Australia. Int J Can 1992; 50: 874-5.
29. [29] Janjua OS, Qureshi SM. Basal cell carcinoma of the head and neck region: an analysis of 171 cases. J Skin Can 2012;2012:943472. doi: 10.1155/2012/943472.
30. [30] Masud D, Moustaki M, Staruch R, Dheansa B. Basal cell carcinomata: Risk factors for incomplete excision and results of re-excision. J Plast Reconstr Aesthet Surg 2016;69:652-6. doi: 10.1016/j.bjps.2015.12.024.
31. [31] Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146: 1-6.
32. [32] Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg 2013;15:337-43. doi: 10.1001/jamafacial.2013.1011.
33. [33] Batra RS, Kelley LC. Predictors of extensive subclinical spread in non-melanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 2002;138:10451.
34. [34] Alam M, Berg D, Bhatia A, et al. Association between number of stages in Mohs micrographic surgery and surgeon, patient, and tumor-specific features: a cross-sectional study of practice patterns of 20 early and mid-career Mohs surgeons. Dermatol Surg 2010;36:1915-20.
35. [35] Delgado Jiménez Y, Camarero-Mulas C, Sanmartín-Jiménez O, et al. Differences of Mohs micrographic surgery in basal cell carcinoma versus squamous cell carcinoma. Int J Dermatol 2018 ;57:1375-81. doi: 10.1111/ijd.14223.
36. [36] Sartore L, Lancerotto L, Salmaso M, et al. Facial basal cell carcinoma: analysis of recurrence and follow-up strategies. Oncol Rep 2011;26:1423-9. doi: 10.3892/or.2011.1453.
37. [37] Smith V, Walton S. Treatment of facial basal cell carcinoma: a review. Journal of Skin Cancer 2011, Article ID 380371 doi: 10.1111/j.1524-4725.2010.01758.x.
38. [38] Sussman LAE, Liggins D F. Incompletely excised basal cell carcinoma: a management dilemma? Aust N Z J Surg 1996;66:276-8. doi: 10.1111/j.1445-2197.1996.tb01184.x
39. [39] Farhi D, Dupin N, Palangie A, Carlotti A, Avril MF. Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg 2007;33:1207-14.
40. [40] Griffiths RW, Suvarna SK, Stone J. Basal cell carcinoma histological clearance margins: an analysis of 1539 conventionally excised tumors. Wider still and deeper? J Plast Reconstr Aesthet Surg 2007 ;60:41-7.
41. [41] Griffiths R W, Suvarna S K, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg 2005;6:795-805.
42. [42] Goh BK, Ang P, Wu YJ, Goh CL. Characteristics of basal cell carcinoma amongst Asians in Singapore and a comparison between completely and incompletely excised tumors. Internat J Dermatol 2006;45: 561-4.
43. [43] Richmond JD, Davie RM. The significance of incomplete excision in patients with basal cell carcinoma. Br J Plast Surg 1987;40:63-7.
44. [44] Goldberg DP. Assessment and surgical treatment of basal cell skin cancer. Clin Plast Surg 1997;24: 673- 86.
45. [45] Durmus Ucar AN, Durmus Kocaaslan FN, Salman A, Demirkesen C, Erdem Bayram F, Bayramicli M. Margin-controlled, staged surgical excision in the treatment of high-risk basal cell carcinomas of the head and neck region. J Cutan Med Surg 2019;23:258-64. doi: 10.1177/1203475418820868.